Results 251 to 260 of about 1,917,601 (292)

Eosinophils in the pathogenesis of paediatric severe asthma

Current Opinion in Allergy & Clinical Immunology, 2014
The importance and functional contribution of eosinophils to the pathogenesis of severe asthma was questioned when adult studies reported neutrophilic inflammation and Th17 cells were central to disease.Eosinophilic inflammation, atopic sensitization and airway remodelling are the hallmark features of severe asthma in children.
Sejal, Saglani, Clare M, Lloyd
openaire   +2 more sources

Mepolizumab for the treatment of severe eosinophilic asthma

American Journal of Health-System Pharmacy, 2017
Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils ...
Mara N, Poulakos, Shawna M, Cargill, Melissa F, Waineo, Allen L, Wolford   +3 more
openaire   +2 more sources

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine
Severe eosinophilic asthma is a distinct asthma phenotype that is characterized by elevated blood eosinophils, frequent exacerbations and dependence on treatment with systemic corticosteroids. The development of Mepolizumab, a monoclonal antibody that targets Interleukin 5, has significantly transformed the therapeutic approach of patients with severe ...
Maria, Kallieri, Andriana I, Papaioannou, Stelios, Loukides   +2 more
openaire   +2 more sources

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2013
In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year.
openaire   +2 more sources

Histamine, Basophils and Eosinophils in Severe Asthma

Clinical Science, 1979
1. Arterial and venous whole blood and plasma histamine concentrations and eosinophil and basophil counts were determined in five patients with acute severe asthma who had not previously received steroid therapy, in five who had been maintained on steroid therapy and in a control group of nine patients with acute non-respiratory illnesses.
T J, Charles, S J, Williams, A, Seaton, C, Bruce, W H, Taylor   +4 more
openaire   +2 more sources

New Horizons for the Treatment of Severe, Eosinophilic Asthma: Benralizumab, a Novel Precision Biologic

Biologics: Targets and Therapy, 2019
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona ...
Marco Caminati, Rachele Vaia, Diego Bagnasco   +2 more
exaly   +1 more source

“Refractory” Eosinophilic Airway Inflammation in Severe Asthma

American Journal of Respiratory and Critical Care Medicine, 2004
Abstract It has been suggested that patients with refractory eosinophilic airway inflammation represent a separate “eosinophilic” asthma phenotype associated with increased morbidity and a poor prognosis. To investigate whether persistent eosinophilia in these patients is a fixed feature or can still be modified by treatment, we ...
ten Brinke, A., Zwinderman, A. H., Sterk, P. J., Rabe, K. F., Bel, E. H.   +4 more
openaire   +2 more sources

Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2016
Asthma affects over 300 million people worldwide and is severe in 10% of sufferers. Severe asthma is associated with greater morbidity and mortality particularly as a consequence of frequent exacerbations. Advances in approaches to phenotype the heterogeneity of severe asthma has established the importance of eosinophilic inflammation and emerging new ...
Richard, Russell, Christopher, Brightling   +1 more
openaire   +2 more sources

Mepolizumab for eosinophilic severe asthma: recent studies

Expert Opinion on Biological Therapy, 2015
In September 2014 two large clinical studies of the anti-IL-5 monoclonal antibody mepolizumab in severe asthma were published in the New England Journal of Medicine (MENSA and SIRIUS).Eosinophilic inflammation has long been recognised as a feature of asthma.
Douglas S, Robinson, Harsha H, Kariyawasam   +1 more
openaire   +2 more sources

Depemokimab (Exdensur) for Severe Eosinophilic Asthma

The Medical Letter on Drugs and Therapeutics
The FDA has approved depemokimab (Exdensur – GSK), a long-acting interleukin-5 (IL-5) antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old. Depemokimab is the fourth IL-5-directed treatment to be approved in the US for this indication; the IL-5 antagonists mepolizumab (Nucala)
openaire   +2 more sources